The supplement will go on sale from September in over 100 Watsons stores in Hong Kong, as well as the Watsons Hong Kong e-store.

ChromaDex CEO and co-founder Frank Jaksch, Jr. said, “We’re excited to have a premier partner in Watsons for the launch of TRU NIAGEN in Asia. They are globally renowned for offering a market-leading product range, and exceptional personalised consultation to educate their consumers.”

Supplementary information

The product features ChromaDex’s NIAGEN NR (nicotinamide riboside), which is said to boost NAD+ (nicotinamide adenine dinucleotide) levels. Nicotinamide riboside is a pyridine-nucleoside form of vitamin B₃.

NAD+ is essential to cellular metabolism and healthy cellular function, with research implying that its decline is associated with a number of age-associated health issues.

The US FDA has granted NIAGEN NR Generally Recognised as Safe (GRAS) status and a New Dietary Ingredient Notification (NDIN).

It has conducted 120 collaborative studies with universities and research institutions such as the National Institute of Aging, MIT and the Scripps Research Institute, amounting to approximately US$50m in additional NR research.

ChromaDex president Robert Fried said, “This critical milestone is the first step in executing our broader expansion plans for TRU NIAGEN.

“With science continually reinforcing just how important NAD+ and this nutrient are to health, we recognise our responsibility to distribute it widely, safely and with the finest partners around the globe.”

Going further afield

After launching the product in Hong Kong, Watsons intends to introduce TRU NIAGEN to retail outlets in Macau and elsewhere in Asia.

Each bottle of the supplement retails for HK$388 (US$50), and multi-bottle packs, as well as yearly subscriptions, will soon be available online.

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: